BL
DNTH icon

Bleichroeder LP’s Dianthus Therapeutics DNTH Stock Holding History

Bleichroeder LP’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-21,664
Closed -$137K – 83
2022
Q4 		$137K Sell
21,664
-8,611
-28% -$152K 0.03% 50
2022
Q3 		$683K Hold
30,275
– – 0.14% 39
2022
Q2 		$581K Hold
30,275
– – 0.12% 42
2022
Q1 		$1.41M Hold
30,275
– – 0.25% 41
2021
Q4 		$2.15M Buy
30,275
+3,125
+12% +$314K 0.34% 44
2021
Q3 		$3.16M Hold
27,150
– – 0.51% 35
2021
Q2 		$4.25M Hold
27,150
– – 0.64% 32
2021
Q1 		$5.14M Hold
27,150
– – 0.87% 24
2020
Q4 		$3.41M Buy
27,150
+5,158
+23% +$585K 0.66% 25
2020
Q3 		$2.39M Hold
21,992
– – 0.43% 33
2020
Q2 		$2.64M Buy
21,992
+6,250
+40% +$881K 0.47% 34
2020
Q1 		$1.58M Buy
+15,742
New +$2.92M 0.41% 38

Other funds holding DNTH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $295M AUM 40.98% 1-Year Est. Return
TG
TCW Group Los Angeles, California $14.9B AUM 46.29% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Bleichroeder LP's DNTH Position: Q1 2023 in Review

Bleichroeder LP sold out of Dianthus Therapeutics (DNTH) in Q1 2023, closing a stake of 21,664 shares — an estimated $137K sold.

Bleichroeder LP first reported a position in DNTH in Q1 2020 and held it in 12 quarters. The position peaked at $5.14M in Q1 2021. 52 funds tracked by Wall St. Rank hold DNTH as of Q1 2023.

  • Bleichroeder LP reported no remaining Dianthus Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Bleichroeder LP sold 21,664 Dianthus Therapeutics shares in Q1 2023, an estimated $137K.
  • Bleichroeder LP first reported a position in Dianthus Therapeutics in Q1 2020 and held it in 12 quarters.
  • Bleichroeder LP's Dianthus Therapeutics position peaked at $5.14M in Q1 2021.
  • 52 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2023.

Based on Bleichroeder LP's 13F filing for Q1 2023, filed 12 May 2023.